SCHEMBL14738880

SCHEMBL14738880

Cn1nc(-c2cnc3c(n2)c(C(=O)NC(C)(C)CO)cn3COC(=O)C(C)(C)C)c2ccc(C#N)cc21

nearest known ligand 0.51

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SYK P43405 13/20 0.51
JAK2 O60674 7/20 0.42
JAK1 P23458 7/20 0.42
JAK3 P52333 6/20 0.42
CYP2D6 P10635 1/20 0.37
KCNH2 Q12809 1/20 0.37
TYK2 P29597 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14737367 0.94 SYK (0.48) SYKJAK2JAK1JAK3KCNH2
SCHEMBL18524449 0.89 SYK (0.52) SYKJAK2JAK1JAK3CYP2D6
SCHEMBL14751416 0.89 SYK (0.53) SYKCYP2D6KCNH2
SCHEMBL14751384 0.82 SYK (0.50) SYKCYP2D6KCNH2
SCHEMBL14737376 0.80 SYK (0.78) SYKJAK2JAK1JAK3CYP2D6
SCHEMBL14737596 0.78 SYK (0.42) SYKJAK2JAK1JAK3CYP2D6
SCHEMBL14738001 0.78 SYK (0.51) SYKJAK2JAK1JAK3
SCHEMBL14738404 0.78 SYK (0.51) SYKJAK2JAK1JAK3
SCHEMBL14737903 0.78 SYK (0.62) SYKJAK2JAK1JAK3CYP2D6
SCHEMBL14738429 0.78 SYK (0.52) SYKJAK2JAK1JAK3CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP disclosed
EP-2763990-B1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2017-02-22 EP disclosed
EP-2763990-A1 PYRROLOPYRAZINE KINASE INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2014-08-13 EP disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US disclosed
US-8658646-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LAROCHE INC. (US) 2014-02-25 US disclosed
WO-2013030138-A1 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2013-03-07 WO disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 US disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 US disclosed
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS HOFFMANN-LA ROCHE INC. 2013-03-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130059834-A1 PYRROLOPYRAZINE KINASE INHIBITORS SYK, ZAP70, JAK1 SYK 1/4885JAK2 5/4885JAK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.